vs
Side-by-side financial comparison of CHIMERA INVESTMENT CORP (CIM) and IOVANCE BIOTHERAPEUTICS, INC. (IOVA). Click either name above to swap in a different company.
IOVANCE BIOTHERAPEUTICS, INC. is the larger business by last-quarter revenue ($86.8M vs $66.2M, roughly 1.3× CHIMERA INVESTMENT CORP). On growth, IOVANCE BIOTHERAPEUTICS, INC. posted the faster year-over-year revenue change (17.7% vs 0.5%). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs 0.8%).
Chimera Investment Corp is a US-based real estate investment trust (REIT) primarily investing in residential mortgage-backed securities, residential and commercial mortgage loans, and other real estate-related financial assets. It delivers sustainable risk-adjusted returns for shareholders via regular dividend distributions from its investment portfolio.
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
CIM vs IOVA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $66.2M | $86.8M |
| Net Profit | $28.3M | — |
| Gross Margin | — | 67.4% |
| Operating Margin | 42.6% | -84.7% |
| Net Margin | 42.8% | — |
| Revenue YoY | 0.5% | 17.7% |
| Net Profit YoY | 119.3% | — |
| EPS (diluted) | $0.05 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $66.2M | $86.8M | ||
| Q3 25 | $65.0M | $67.5M | ||
| Q2 25 | $66.0M | $60.0M | ||
| Q1 25 | $69.2M | $49.3M | ||
| Q4 24 | $65.8M | $73.7M | ||
| Q3 24 | $66.5M | $58.6M | ||
| Q2 24 | $67.3M | $31.1M | ||
| Q1 24 | $65.1M | $715.0K |
| Q4 25 | $28.3M | — | ||
| Q3 25 | $-580.0K | $-91.3M | ||
| Q2 25 | $35.5M | $-111.7M | ||
| Q1 25 | $167.3M | $-116.2M | ||
| Q4 24 | $-146.5M | — | ||
| Q3 24 | $136.5M | $-83.5M | ||
| Q2 24 | $56.7M | $-97.1M | ||
| Q1 24 | $129.5M | $-113.0M |
| Q4 25 | — | 67.4% | ||
| Q3 25 | — | 43.0% | ||
| Q2 25 | — | 5.5% | ||
| Q1 25 | — | -0.8% | ||
| Q4 24 | — | 68.7% | ||
| Q3 24 | — | 46.2% | ||
| Q2 24 | — | -0.8% | ||
| Q1 24 | — | — |
| Q4 25 | 42.6% | -84.7% | ||
| Q3 25 | -0.5% | -140.7% | ||
| Q2 25 | 54.3% | -189.8% | ||
| Q1 25 | — | -245.8% | ||
| Q4 24 | -222.6% | -117.5% | ||
| Q3 24 | — | -152.1% | ||
| Q2 24 | 84.2% | -327.6% | ||
| Q1 24 | — | -16464.6% |
| Q4 25 | 42.8% | — | ||
| Q3 25 | -0.9% | -135.3% | ||
| Q2 25 | 53.7% | -186.2% | ||
| Q1 25 | 241.7% | -235.5% | ||
| Q4 24 | -222.6% | — | ||
| Q3 24 | 205.4% | -142.7% | ||
| Q2 24 | 84.2% | -312.2% | ||
| Q1 24 | 198.8% | -15800.8% |
| Q4 25 | $0.05 | — | ||
| Q3 25 | $-0.27 | — | ||
| Q2 25 | $0.17 | $-0.33 | ||
| Q1 25 | $1.77 | $-0.36 | ||
| Q4 24 | $-2.06 | $-0.24 | ||
| Q3 24 | $1.39 | $-0.28 | ||
| Q2 24 | $0.41 | $-0.34 | ||
| Q1 24 | $1.36 | $-0.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $278.6M | $297.0M |
| Total DebtLower is stronger | $251.5M | — |
| Stockholders' EquityBook value | $2.6B | $698.6M |
| Total Assets | $15.8B | $913.2M |
| Debt / EquityLower = less leverage | 0.10× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $278.6M | $297.0M | ||
| Q3 25 | $491.5M | $300.8M | ||
| Q2 25 | $250.2M | $301.2M | ||
| Q1 25 | $253.3M | $359.7M | ||
| Q4 24 | $84.0M | $323.8M | ||
| Q3 24 | $97.3M | $397.5M | ||
| Q2 24 | $162.3M | $412.5M | ||
| Q1 24 | $169.0M | $356.2M |
| Q4 25 | $251.5M | — | ||
| Q3 25 | $251.0M | — | ||
| Q2 25 | $135.2M | — | ||
| Q1 25 | $134.9M | — | ||
| Q4 24 | $134.6M | — | ||
| Q3 24 | $134.4M | — | ||
| Q2 24 | $62.4M | — | ||
| Q1 24 | — | — |
| Q4 25 | $2.6B | $698.6M | ||
| Q3 25 | $2.6B | $702.3M | ||
| Q2 25 | $2.6B | $698.5M | ||
| Q1 25 | $2.6B | $767.9M | ||
| Q4 24 | $2.5B | $710.4M | ||
| Q3 24 | $2.7B | $773.5M | ||
| Q2 24 | $2.6B | $768.5M | ||
| Q1 24 | $2.6B | $680.0M |
| Q4 25 | $15.8B | $913.2M | ||
| Q3 25 | $15.1B | $904.9M | ||
| Q2 25 | $14.9B | $907.4M | ||
| Q1 25 | $13.2B | $966.7M | ||
| Q4 24 | $13.1B | $910.4M | ||
| Q3 24 | $13.7B | $991.1M | ||
| Q2 24 | $13.1B | $964.3M | ||
| Q1 24 | $12.5B | $869.8M |
| Q4 25 | 0.10× | — | ||
| Q3 25 | 0.10× | — | ||
| Q2 25 | 0.05× | — | ||
| Q1 25 | 0.05× | — | ||
| Q4 24 | 0.05× | — | ||
| Q3 24 | 0.05× | — | ||
| Q2 24 | 0.02× | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-248.9M | $-52.6M |
| Free Cash FlowOCF − Capex | — | $-61.9M |
| FCF MarginFCF / Revenue | — | -71.3% |
| Capex IntensityCapex / Revenue | — | 10.7% |
| Cash ConversionOCF / Net Profit | -8.78× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-336.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-248.9M | $-52.6M | ||
| Q3 25 | $-137.5M | $-78.7M | ||
| Q2 25 | $-7.4M | $-67.4M | ||
| Q1 25 | $48.8M | $-103.7M | ||
| Q4 24 | $205.7M | $-73.3M | ||
| Q3 24 | $41.4M | $-59.0M | ||
| Q2 24 | $69.0M | $-98.4M | ||
| Q1 24 | $57.3M | $-122.3M |
| Q4 25 | — | $-61.9M | ||
| Q3 25 | — | $-89.5M | ||
| Q2 25 | — | $-74.9M | ||
| Q1 25 | — | $-109.9M | ||
| Q4 24 | — | $-77.5M | ||
| Q3 24 | — | $-61.3M | ||
| Q2 24 | — | $-98.9M | ||
| Q1 24 | — | $-126.5M |
| Q4 25 | — | -71.3% | ||
| Q3 25 | — | -132.7% | ||
| Q2 25 | — | -124.9% | ||
| Q1 25 | — | -222.8% | ||
| Q4 24 | — | -105.1% | ||
| Q3 24 | — | -104.6% | ||
| Q2 24 | — | -317.9% | ||
| Q1 24 | — | -17685.3% |
| Q4 25 | — | 10.7% | ||
| Q3 25 | — | 16.1% | ||
| Q2 25 | — | 12.4% | ||
| Q1 25 | — | 12.6% | ||
| Q4 24 | — | 5.7% | ||
| Q3 24 | — | 3.9% | ||
| Q2 24 | — | 1.4% | ||
| Q1 24 | — | 583.4% |
| Q4 25 | -8.78× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -0.21× | — | ||
| Q1 25 | 0.29× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.30× | — | ||
| Q2 24 | 1.22× | — | ||
| Q1 24 | 0.44× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CIM
Segment breakdown not available.
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
